(Q33401434)

English

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Luis Leon

1

0 references

Margarita Amenedo

7

object named as

Margarita Amenedo

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Sergio Vázquez

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

José Manuel Gracia

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joaquín Casal

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martín Lazaro

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

José Luis Firvida

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lucia Santome

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sonia Macia

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

25 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1389-1396

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Chemotherapy in NSCLC: historical review

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of r

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Lung cancer--time to move on from chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Histology matters: individualizing treatment in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

The emerging role of biomarkers in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Maintenance therapy in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Angiogenesis in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

A comparison of phase II study strategies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Targeting VEGF in lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.693165

21 January 2018

Identifiers

10.1517/14656566.2012.693165

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33401434&oldid=1743863687"